

Robert L Ali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8572464/publications.pdf>

Version: 2024-02-01

164
papers

9,653
citations

71102

41
h-index

43889

91
g-index

166
all docs

166
docs citations

166
times ranked

9323
citing authors

#	ARTICLE	IF	CITATIONS
1	A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia. <i>Drug and Alcohol Review</i> , 2022, 41, 309-319.	2.1	8
2	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
3	End compulsory drug treatment in the Asia-Pacific region. <i>Lancet, The</i> , 2022, 399, 419-421.	13.7	1
4	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	2.1	7
5	â€˜The Drug Survey Appâ€™™: a protocol for developing and validating an interactive population survey tool for drug use among Aboriginal and Torres Strait Islander Australians. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 17.	2.6	2
6	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001â€˜2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	3.2	7
7	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	1.9	10
8	Quality of life as a predictor of time to heroin relapse among male residents following release from compulsory rehabilitation centres in Vietnam. <i>Drug and Alcohol Review</i> , 2021, 40, 296-306.	2.1	5
9	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001â€˜2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	3.2	5
10	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001â€˜2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	3.2	10
11	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15â€˜year retrospective cohort study. <i>Addiction</i> , 2021, 116, 3139-3152.	3.3	14
12	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	3.3	3
13	Brief Intervention for Illicit Drug Use. , 2021, , 655-671.		0
14	Revision of the Australian guidelines to reduce health risks from drinking alcohol. <i>Medical Journal of Australia</i> , 2021, 215, 518-524.	1.7	13
15	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
16	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108262.	3.2	15
17	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
18	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50

#	ARTICLE	IF	CITATIONS
19	Response to commentaries. <i>Addiction</i> , 2019, 114, 1357-1358.	3.3	0
20	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	13.7	169
21	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , 2019, 114, 1346-1353.	3.3	45
22	Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. <i>Journal of Addiction Medicine</i> , 2018, 12, 234-240.	2.6	18
23	Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2018, 87, 9-15.	2.8	14
24	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166.	7.4	28
25	Improving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals' attitudes and clinical practice. <i>Journal of European CME</i> , 2018, 7, 1506197.	1.6	2
26	Latent Psychotic Symptom Profiles Amongst People Who Use Methamphetamine: What Do They Tell Us About Existing Diagnostic Categories?. <i>Frontiers in Psychiatry</i> , 2018, 9, 578.	2.6	8
27	Participant perspectives on the Australian WHO ASSIST Phase III brief intervention for illicit drug use in a primary healthcare setting. <i>Australian Journal of Primary Health</i> , 2018, 24, 518.	0.9	0
28	A randomised controlled trial of a brief intervention for illicit drug use linked to ASSIST screening in a primary healthcare setting: results from the Australian component of the World Health Organization Phase III ASSIST studies. <i>Australian Journal of Primary Health</i> , 2018, 24, 149.	0.9	8
29	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31
30	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
31	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018, 8, e020723.	1.9	11
32	Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. <i>Journal of Substance Abuse Treatment</i> , 2017, 76, 69-76.	2.8	15
33	Opioid antagonists with minimal sedation for opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002021.	2.8	35
34	Feasibility of Studying a Brief Intervention to Help Chinese Villagers with Problem Alcohol Use After an Earthquake. <i>Alcohol and Alcoholism</i> , 2017, 52, 472-476.	1.6	11
35	Buprenorphine for managing opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002025.	2.8	66
36	Strengthening advocacy efforts with empirical evidence: A case example of the conduct, uptake and utilisation of research in drug policy decision-making in Vietnam. <i>International Journal of Drug Policy</i> , 2017, 49, 41-47.	3.3	1

#	ARTICLE	IF	CITATIONS
37	The political and scientific challenges in evaluating compulsory drug treatment centers in Southeast Asia. <i>Harm Reduction Journal</i> , 2017, 14, 2.	3.2	18
38	The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology. , 2016, , 649-659.		1
39	Ethical considerations when researching with pregnant substance users and implications for practice. <i>Addictive Behaviors</i> , 2016, 60, 242-243.	3.0	3
40	Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam. <i>Drug and Alcohol Dependence</i> , 2016, 168, 147-155.	3.2	22
41	Alpha ₂ -adrenergic agonists for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2016, 2016, CD002024.	2.8	122
42	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11
43	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91.	2.1	15
44	The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. <i>Drug and Alcohol Review</i> , 2016, 35, 76-82.	2.1	21
45	Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. <i>Psychiatry Research</i> , 2016, 238, 166-171.	3.3	28
46	Analysis of qualitative data from the investigation study in pregnancy of the ASSIST Version 3.0 (the Tj ETQq0 0 0 ggBT /Overlock 10 Tf 2.3	2.3	11
47	Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. <i>Harm Reduction Journal</i> , 2015, 12, 31.	3.2	28
48	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610.	2.1	8
49	Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015, 34, 623-629.	2.1	6
50	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	2.1	10
51	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1321-1333.	1.9	4
52	Brief Intervention for Illicit Drug Users. , 2015, , 293-312.		0
53	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	3.2	29
54	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	3.3	19

#	ARTICLE	IF	CITATIONS
55	Global statistics on addictive behaviours: 2014 status report. <i>Addiction</i> , 2015, 110, 904-919.	3.3	311
56	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 51-61.	2.8	20
57	The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014, 136, 21-27.	3.2	43
58	Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT). <i>Drug and Alcohol Dependence</i> , 2014, 139, 121-131.	3.2	22
59	Alpha ₂ -adrenergic agonists for the management of opioid withdrawal. , 2014, , CD002024.		44
60	Pharmacogenomics of methadone maintenance treatment. <i>Pharmacogenomics</i> , 2014, 15, 1007-1027.	1.3	43
61	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	3.2	14
62	Pharmacotherapies for cannabis dependence. <i>The Cochrane Library</i> , 2014, , CD008940.	2.8	94
63	Ultra-rapid screening for substance-use disorders: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite). <i>Drug and Alcohol Dependence</i> , 2013, 132, 352-361.	3.2	95
64	A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2013, 131, 119-126.	3.2	39
65	Methadone at tapered doses for the management of opioid withdrawal. <i>The Cochrane Library</i> , 2013, , CD003409.	2.8	92
66	Dose-Related Psychotic Symptoms in Chronic Methamphetamine Users. <i>JAMA Psychiatry</i> , 2013, 70, 319.	11.0	170
67	Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in Pregnancy. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 123-135.	0.5	9
68	Screening for use of alcohol, tobacco and cannabis in pregnancy using self-report tools. <i>Journal of Developmental Origins of Health and Disease</i> , 2012, 3, 216-223.	1.4	0
69	Predictive factors for treatment retention in methadone programs in Indonesia. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 239-246.	2.8	52
70	Drug policy in Vietnam: A decade of change?. <i>International Journal of Drug Policy</i> , 2012, 23, 319-326.	3.3	42
71	A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. <i>Addiction</i> , 2012, 107, 957-966.	3.3	167
72	Evaluating the impact of community-based treatment options on methamphetamine use: findings from the M ₂ T ₂ E ₂ S ₂ study (MATES). <i>Addiction</i> , 2012, 107, 1998-2008.	3.3	108

#	ARTICLE	IF	CITATIONS
73	Cochrane systematic reviews in the field of addiction: What's there and what should be. <i>Drug and Alcohol Dependence</i> , 2011, 113, 96-103.	3.2	26
74	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011, 118, 265-273.	3.2	62
75	Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 959-964.	4.8	77
76	Oral substitution treatment of injecting opioid users for prevention of HIV infection. <i>The Cochrane Library</i> , 2011, , CD004145.	2.8	197
77	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. <i>Drug and Alcohol Review</i> , 2011, 30, 613-620.	2.1	21
78	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>The Cochrane Library</i> , 2010, , CD002022.	2.8	41
79	Methamphetamine Psychosis in Australia, Philippines, and Thailand. <i>Addictive Disorders and Their Treatment</i> , 2010, 9, 143-149.	0.5	10
80	Mood Disturbance and Withdrawal Severity in Substitution Treatment for Opioid Dependence. <i>Addictive Disorders and Their Treatment</i> , 2010, 9, 1-7.	0.5	0
81	United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: Treatnet. <i>Substance Abuse</i> , 2010, 31, 251-263.	2.3	17
82	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. <i>Medical Journal of Australia</i> , 2009, 191, 161-165.	1.7	40
83	Buprenorphine for the management of opioid withdrawal. , 2009, , CD002025.		124
84	Alpha2-adrenergic agonists for the management of opioid withdrawal. , 2009, , CD002024.		39
85	Opioid antagonists with minimal sedation for opioid withdrawal. , 2009, , CD002021.		27
86	The rise of methamphetamine in Southeast and East Asia. <i>Drug and Alcohol Review</i> , 2008, 27, 220-228.	2.1	128
87	Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 248-254.	1.0	35
88	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008, 103, 462-468.	3.3	161
89	Validation of the alcohol, smoking and substance involvement screening test (ASSIST). <i>Addiction</i> , 2008, 103, 1039-1047.	3.3	825
90	Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. <i>Addiction</i> , 2008, 103, 1484-1492.	3.3	192

#	ARTICLE	IF	CITATIONS
91	Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 640-7.	2.4	17
92	Substitution treatment of injecting opioid users for prevention of HIV infection. , 2008, , CD004145.		98
93	Ensuring the safety of new medications and devices: are naltrexone implants safe?. <i>Medical Journal of Australia</i> , 2008, 188, 438-439.	1.7	11
94	A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). <i>Addictive Behaviors</i> , 2006, 31, 371-387.	3.0	21
95	One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). <i>Drug and Alcohol Dependence</i> , 2006, 83, 174-180.	3.2	118
96	Opioid antagonists with minimal sedation for opioid withdrawal. , 2006, , CD002021.		9
97	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. , 2006, , CD002022.		10
98	The place of detoxification in treatment of opioid dependence. <i>Current Opinion in Psychiatry</i> , 2006, 19, 266-270.	6.3	27
99	Short-term Outcomes for the Treatment of Heroin Dependence. <i>Addictive Disorders and Their Treatment</i> , 2006, 5, 133-143.	0.5	23
100	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. <i>Addictive Disorders and Their Treatment</i> , 2006, 5, 155-164.	0.5	15
101	Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. <i>Drug and Alcohol Review</i> , 2006, 25, 123-130.	2.1	9
102	Buprenorphine for the management of opioid withdrawal. , 2006, , CD002025.		55
103	BRIEF REPORT: Methadone Treatment of Injecting Opioid Users for Prevention of HIV Infection. <i>Journal of General Internal Medicine</i> , 2006, 21, 193-195.	2.6	66
104	Methadone at tapered doses for the management of opioid withdrawal. , 2005, , CD003409.		56
105	The first methadone clinic in Beijing. <i>Drug and Alcohol Review</i> , 2005, 24, 285-287.	2.1	6
106	Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. <i>Drug and Alcohol Review</i> , 2005, 24, 217-226.	2.1	220
107	The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). <i>Drug and Alcohol Review</i> , 2005, 24, 411-418.	2.1	204
108	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005, 16, 67-75.	3.3	55

#	ARTICLE	IF	CITATIONS
109	Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS). <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 255-263.	2.8	76
110	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. <i>Addictive Behaviors</i> , 2005, 30, 443-456.	3.0	23
111	HIV in injecting drug users in Asian countries: Authors' reply. <i>BMJ: British Medical Journal</i> , 2005, 330, 147.2.	2.3	0
112	HIV in injecting drug users in Asian countries. <i>BMJ: British Medical Journal</i> , 2004, 329, 697-698.	2.3	10
113	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 536-541.	2.4	17
114	Heroin users in Australia: population trends. <i>Drug and Alcohol Review</i> , 2004, 23, 107-116.	2.1	35
115	Asia Pacific Column. <i>Drug and Alcohol Review</i> , 2004, 23, 133-134.	2.1	0
116	Impact of the heroin "drought" on patterns of drug use and drug-related harms. <i>Drug and Alcohol Review</i> , 2004, 23, 143-150.	2.1	23
117	Amphetamines in Asia: the value of information networks. <i>Drug and Alcohol Review</i> , 2004, 23, 235-237.	2.1	2
118	Substance use and treatment options in Cambodia. <i>Drug and Alcohol Review</i> , 2004, 23, 365-367.	2.1	3
119	Alpha2 adrenergic agonists for the management of opioid withdrawal. , 2004, , CD002024.		18
120	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. <i>Drug and Alcohol Review</i> , 2003, 22, 425-431.	2.1	11
121	Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. <i>Addiction</i> , 2003, 98, 413-418.	3.3	33
122	Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <i>Addiction</i> , 2003, 98, 441-452.	3.3	246
123	Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. <i>Drug and Alcohol Dependence</i> , 2003, 71, 295-302.	3.2	101
124	Psychotic symptoms in methamphetamine psychotic in-patients. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 347-352.	2.1	164
125	Accidental Fatalities Among Heroin Users in South Australia, 1994-1997: Toxicological Findings and Circumstances of Death. <i>Addiction Research and Theory</i> , 2002, 10, 335-346.	1.9	18
126	Harm Minimization in a Prohibition Context—Australia. <i>Annals of the American Academy of Political and Social Science</i> , 2002, 582, 80-93.	1.6	12

#	ARTICLE	IF	CITATIONS
127	Comment on: Doverty et al., Hyperalgesic responses in methadone maintenance patients (Pain) Tj ETQq1 1 0.784314 rgBT /Qverlock 10	4.2	1
128	Relationship between LAAM and methadone preference and treatment outcomes. Drug and Alcohol Dependence, 2002, 66, 295-301.	3.2	23
129	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug and Alcohol Dependence, 2002, 68, 5-14.	3.2	41
130	Which substitution pharmacotherapy is most effective in treating opioid dependence?. Medical Journal of Australia, 2002, 176, 493-494.	1.7	0
131	Adrenergic agonists in opioid withdrawal. Addiction, 2002, 97, 49-58.	3.3	63
132	The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction, 2002, 97, 1183-1194.	3.3	1,344
133	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction, 2002, 97, 771-772.	3.3	101
134	The health effects of ecstasy: a literature review. Drug and Alcohol Review, 2002, 21, 53-63.	2.1	126
135	Harm Minimization in a Prohibition Context—Australia. Annals of the American Academy of Political and Social Science, 2002, 582, 80-93.	1.6	3
136	Hyperalgesic responses in methadone maintenance patients. Pain, 2001, 90, 91-96.	4.2	272
137	Cochrane drugs and alcohol group: the development of systematic reviews of treatment outcome. Alcohol and Alcoholism, 2001, 36, 109-111.	1.6	1
138	Overdose Among Heroin Users: Evaluation of an Intervention in South Australia. Addiction Research and Theory, 2001, 9, 481-501.	1.9	15
139	Systematic review processes and the management of opioid withdrawal. Australian and New Zealand Journal of Public Health, 2000, 24, 427-431.	1.8	5
140	The management of opioid withdrawal. Drug and Alcohol Review, 2000, 19, 309-318.	2.1	15
141	A Training, Authorisation and Review Process for Methadone Prescribers. Journal of Maintenance in the Addictions, 2000, 1, 15-25.	0.1	4
142	The Impact of Cannabis Decriminalisation in Australia and the United States. Journal of Public Health Policy, 2000, 21, 157.	2.0	71
143	Heroin overdose: Responding to the epidemic. Australian and New Zealand Journal of Psychiatry, 2000, 34, A1-A2.	2.3	0
144	Accidental drug toxicity associated with methadone maintenance treatment. Medical Journal of Australia, 1999, 170, 100-101.	1.7	6

#	ARTICLE	IF	CITATIONS
145	A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. <i>Addiction</i> , 1999, 94, 1279-1298.	3.3	154
146	Characteristics of amphetamine users seeking information, help and treatment in Adelaide, South Australia. <i>Drug and Alcohol Review</i> , 1999, 18, 63-73.	2.1	18
147	Laws applying to minor cannabis offences in Australia and their evaluation. <i>International Journal of Drug Policy</i> , 1999, 10, 299-303.	3.3	4
148	Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. <i>Drug and Alcohol Review</i> , 1998, 17, 187-195.	2.1	33
149	Correlates of retention on the South Australian Methadone Program 1981-91. <i>Australian and New Zealand Journal of Public Health</i> , 1998, 22, 771-776.	1.8	11
150	Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. <i>Addiction</i> , 1998, 93, 701-711.	3.3	175
151	Therapeutic use of cannabis: clarifying the debate. <i>Drug and Alcohol Review</i> , 1998, 17, 445-452.	2.1	3
152	HIV prevalence and risk behaviour in needle exchange attenders: a national study. <i>Medical Journal of Australia</i> , 1997, 166, 237-240.	1.7	68
153	Improvements in retention rates and changes in client group with methadone maintenance streaming. <i>Drug and Alcohol Review</i> , 1996, 15, 83-88.	2.1	18
154	HIV infection among injecting drug users in the South Australian methadone program. <i>Medical Journal of Australia</i> , 1995, 162, 242-244.	1.7	4
155	In-patient treatment for the alcohol-dependent person: a public health perspective. <i>Drug and Alcohol Review</i> , 1994, 13, 195-202.	2.1	3
156	Injecting behaviour and risky needle use amongst methadone maintenance clients. <i>Drug and Alcohol Dependence</i> , 1994, 34, 113-119.	3.2	14
157	Hepatitis C and the history of injecting drug use in South Australia. <i>Medical Journal of Australia</i> , 1994, 161, 286-286.	1.7	7
158	The prescription of methadone for opiate dependence in Australia, 1985-1991. <i>Medical Journal of Australia</i> , 1993, 159, 107-108.	1.7	6
159	Bloody needles. <i>Aids</i> , 1991, 5, 1025-1028.	2.2	50
160	HIV prevalence and risk behaviours for HIV transmission in South Australian prisons. <i>Aids</i> , 1991, 5, 845-852.	2.2	34
161	Risk of transmission of the human immunodeficiency virus in the prison setting. <i>Medical Journal of Australia</i> , 1990, 153, 434-434.	1.7	1
162	PREVENTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AMONG PRISONERS: PRISONERS' AND PRISON OFFICERS' KNOWLEDGE OF HIV AND THEIR ATTITUDES TO OPTIONS FOR PREVENTION. <i>Community Health Studies</i> , 1990, 14, 61-64.	0.0	1

#	ARTICLE	IF	CITATIONS
163	Risk of transmission of the human immunodeficiency virus in the prison setting. Medical Journal of Australia, 1989, 150, 722-722.	1.7	10
164	Regulation and Decriminalisation of Illegal Substances in Thailand. Journal of Health Science and Medical Research, 0, , .	0.1	0